TPPI Antibody

TPPI Biology and Clinical Significance

TPPI (EC 3.4.14.9) is a lysosomal exopeptidase responsible for cleaving tripeptides from protein substrates during degradation. Key features include:

• Structure: A 69 kDa zymogen precursor processed into a 48 kDa mature enzyme through autocatalysis in acidic environments .

• Function: Essential for lysosomal proteolysis; mutations cause LINCL, characterized by neuronal degeneration and premature death .

• Therapeutic Target: Gene therapy restoring ≥6% of normal TPPI activity slows neurodegeneration in murine models .

Development and Applications of TPPI Antibodies

TPPI antibodies are primarily used to study enzyme localization, expression, and therapeutic efficacy in disease models.

Key Antibody Characteristics

Applications:

• Disease Modeling: Detects TPPI expression in brain tissues of LINCL murine models to assess gene therapy outcomes .

• Mechanistic Studies: Identifies structural residues (e.g., W542) critical for TPPI’s catalytic activity and autocatalytic processing .

Table 1: Key Studies Involving TPPI Antibodies

Critical Insights:

• Residue W542: Essential for substrate binding and autocatalysis; mutations impair TPPI’s lysosomal trafficking .

• Therapeutic Threshold: ≥6% TPPI activity significantly delays symptom onset in mice .

Challenges and Future Directions

• Antibody Specificity: Cross-reactivity with homologous peptidases (e.g., TPPII) requires rigorous validation .

• Clinical Translation: Antibodies enable monitoring of TPPI restoration in gene therapies, but systemic delivery hurdles persist .